Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2

被引：0

作者：

Cocco, Emiliano ^{[1
]}

Carmona, F. Javier ^{[1
]}

Won, Helen H. ^{[1
]}

Berger, Michael F. ^{[1
]}

Hyman, David M. ^{[1
]}

Rossi, Valentina ^{[2
]}

Chan, Carmen ^{[1
]}

Moriarty, Alyssa ^{[3
]}

Papadopoulos, Kyriakos P. ^{[3
]}

Wick, Michael J. ^{[3
]}

Cownie, James ^{[1
]}

Sarotto, Ivana ^{[2
]}

Cutler, Richard E. ^{[4
]}

Avogadri-Connors, Francesca ^{[4
]}

Savas, Peter ^{[5
]}

Lalani, Alshad S. ^{[4
]}

Boni, Valentina ^{[6
]}

Loi, Sherene ^{[5
]}

Baselga, Jose ^{[1
]}

Montemurro, Filippo ^{[2
]}

Scaltriti, Maurizio ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Inst Candiolo IRCCs, Fdn Piemonte Oncol, Candiolo, Italy

[3] START Ctr, South Texas Accelerated Res Therapeut, San Antonio, TX USA

[4] Puma Biotechnol Inc, Los Angeles, CA USA

[5] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[6] Hosp Univ Madrid Sanchinarro, START Madrid, Ctr Integral Oncol Clara Campal, Madrid, Spain

来源：

关键词：

D O I：

10.1158/1535-7163.TARG-17-B169

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B169

引用

页数：3